Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. (JSPR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · JSPR · as of Sep 30, 2025
Ownership Breakdown
64
Institutional Holders
▼ 4 vs Q2
$47.82M
Total Inst. Value
▼ $21.64M vs Q2
16.25M
Shares Outstanding
freeFloat 84.78%
20.16M
13F Shares Held
▲ 7.64M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
JSPR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VELAN CAPITAL INVESTMENT MANAGEMENT LP biological products, (no diagnostic substances) | 2.67M | 17.76% | 17.76% | $6.21B | Nov 14, 2025 | ▲ 1.23M |
SOLEUS CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.49M | 9.95% | 9.95% | $3.56B | Nov 14, 2025 | — held |
ACORN CAPITAL ADVISORS, LLC biological products, (no diagnostic substances) | 1.38M | 9.20% | 9.20% | $3.29B | Nov 17, 2025 | NEW |
KINGDON CAPITAL MANAGEMENT, L.L.C. biological products, (no diagnostic substances) | 1.32M | 8.82% | 8.82% | $3.15B | Nov 14, 2025 | ▲ 640.1K |
ROCK SPRINGS CAPITAL MANAGEMENT LP biological products, (no diagnostic substances) | 1.10M | 7.33% | 7.33% | $2.62B | Nov 14, 2025 | ▲ 555.6K |
CARLYLE GROUP INC. biological products, (no diagnostic substances) | 1.07M | 7.10% | 7.10% | $2.53B | Nov 7, 2025 | — held |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 1.04M | 6.92% | 6.92% | $2.47B | Nov 14, 2025 | NEW |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.03M | 6.88% | 6.88% | $2.46B | Nov 7, 2025 | ▲ 408.2K |
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. biological products, (no diagnostic substances) | 1.03M | 6.85% | 6.85% | $2.45B | Nov 14, 2025 | ▲ 325.2K |
PROPEL BIO MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.03M | 6.85% | 6.85% | $2.45B | Nov 12, 2025 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
15
Increased
+4.74M shares13
New Positions
first time holders16
Decreased
−749.8K shares0
Sold Out
fully exitedNet shares change (top 50)
+3.99M
+4.74M / −749.8K
Net new holders
+12
13 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
JSPR insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
15
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Mahal Jeetinder Singh CEO and President | Feb 6, 2026 | Award | 500,000 | $1.35 | $675.0K | 500.0K | Form 4 ↗ |
MARTELL RON President, CEO and Director | Jan 2, 2026 | Award | 234,000 | $1.84 | $430.6K | 234.0K | Form 4 ↗ |
Mahal Jeetinder Singh Chief Operating Officer | Jan 2, 2026 | Award | 90,000 | $1.84 | $165.6K | 90.0K | Form 4 ↗ |
CROSS HERB Chief Financial Officer | Jan 2, 2026 | Award | 90,000 | $1.84 | $165.6K | 90.0K | Form 4 ↗ |
WIGGANS THOMAS G director | Sep 22, 2025 | Purchase | 41,000 | $2.43 | $99.6K | 41.0K | Form 4 ↗ |
WIGGANS THOMAS G director | Sep 22, 2025 | Purchase | 41,000 | $2.92 | $119.7K | 41.0K | Form 4 ↗ |
Lucas Svetlana director | Sep 22, 2025 | Purchase | 20,000 | $2.43 | $48.6K | 20.0K | Form 4 ↗ |
Lucas Svetlana director | Sep 22, 2025 | Purchase | 20,000 | $2.92 | $58.4K | 20.0K | Form 4 ↗ |
MARTELL RON President and CEO | Sep 22, 2025 | Purchase | 41,000 | $2.43 | $99.6K | 74.1K | Form 4 ↗ |
MARTELL RON President and CEO | Sep 22, 2025 | Purchase | 41,000 | $2.92 | $119.7K | 41.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Jasper Therapeutics, Inc. (JSPR) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 15.22%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Jasper Therapeutics, Inc. is VELAN CAPITAL INVESTMENT MANAGEMENT LP, holding approximately 2.67 million shares — equal to 17.76% of outstanding shares — as of September 30, 2025.
A total of 64 institutional investors currently hold JSPR stock, with a combined institutional value of approximately $47,815,871 as of the most recent 13F filing period.
Frequently asked questions
JSPR ownershipJasper Therapeutics, Inc. (JSPR) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is VELAN CAPITAL INVESTMENT MANAGEMENT LP with a 17.76% stake. Company insiders hold 15.22%. Data sourced from SEC Form 13F as of September 30, 2025.